/BBNX

BBNX Stock - Beta Bionics, Inc.

Q: What is the analyst price target for BBNX?

Analyst price target information is not currently available for BBNX.

Q: What is BBNX's market cap?

Market capitalization information is not currently available for BBNX.

Healthcare|Medical - Equipment & Services|NASDAQ

$17.27-2.15%

$0.38 (-2.15%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+87.2%upside

Target: $32.33

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BBNX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta5.74

52W High$32.71

52W Low$8.89

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022
Revenue	$65.12M	$11.99M	$179,000
Gross Profit	$35.89M	$6.31M	$179,000
Gross Margin	55.1%	52.6%	100.0%
Operating Income	$-45,251,000	$-35,850,000	$-65,844,000
Net Income	$-54,756,000	$-44,099,000	$-64,751,000
Net Margin	-84.1%	-367.6%	-36173.7%
EPS	$-8.60	$-8.31	$-12.96

Company Overview

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Visit Website

Earnings History & Surprises

BBNX

Beat Rate

50%

Last 4 quarters

Avg Surprise

-71.3%

EPS vs Estimate

Beats / Misses

2/2

Last 12 quarters

Latest EPS

$-0.33

Q4 2025

EPS Surprise History

Q3 23

No data

Q4 23

No data

Q1 25

No data

Q1 25

-333.3%

$-1.82vs$-0.42

Q2 25

-2.0%

$-0.52vs$-0.51

Q3 25

+23.5%

$-0.39vs$-0.51

Q4 25

+26.7%

$-0.33vs$-0.45

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 24, 2026	$-0.41	—	—	—
Q1 2026	Feb 17, 2026	$-0.41	—	—	—
Q4 2025	Oct 28, 2025	$-0.45	$-0.33	+26.7%	✓ BEAT
Q3 2025	Jul 29, 2025	$-0.51	$-0.39	+23.5%	✓ BEAT
Q2 2025	May 6, 2025	$-0.51	$-0.52	-2.0%	✗ MISS
Q1 2025	Mar 25, 2025	$-0.42	$-1.82	-333.3%	✗ MISS
Q1 2025	Jan 31, 2025	—	$-1.55	—	—
Q4 2023	Dec 31, 2023	—	$-3.13	—	—
Q3 2023	Sep 30, 2023	—	$-1.71	—	—

Frequently Asked Questions about BBNX

What is BBNX's current stock price?

Beta Bionics, Inc. (BBNX) is currently trading at $17.27 per share. The stock has moved -2.15% today.

What is the analyst price target for BBNX?

The average analyst price target for BBNX is $32.33, based on 1 analyst.

What sector is Beta Bionics, Inc. in?

Beta Bionics, Inc. operates in the Healthcare sector, specifically within the Medical - Equipment & Services industry. The company is traded on the NASDAQ exchange.

What is BBNX's market cap?

Beta Bionics, Inc. has a market capitalization of $0.76 billion, making it a small-cap company.

Does BBNX pay dividends?

No, Beta Bionics, Inc. does not currently pay a dividend to shareholders.